MeSH tree: D12.776.124.790.651.114.224.060
After combing through 4,000 existing medications, an artificial intelligence tool helped uncover one that saved the life of a patient with idiopathic multicentric Castleman's disease (iMCD). This rare disease has an especially ...
Feb 5, 2025
0
52
Patients whose metastatic colorectal cancer has progressed following chemotherapy and who lack mutations in the RAS and BRAF genes (RAS/BRAF wild-type) are typically treated with EGFR inhibitors. For those whose tumors also ...
Jan 29, 2025
0
11
A Peter Mac-led international clinical trial has shown adding an immunotherapy drug to the chemotherapy that patients receive ahead of surgery can dramatically improve breast cancer cure rates.
Jan 28, 2025
0
45
Results from the Phase III NRG Oncology RTOG 0920 (NRG-RTOG 0920) trial assessing postoperative radiotherapy with or without concurrent cetuximab for selected patients with squamous cell cancer of the head and neck (SCCHN) ...
Jan 27, 2025
0
15
Neuroblastoma is the most common extracranial solid tumor in children, with nearly 50% of cases diagnosed at an advanced stage, often with metastatic disease. Despite advances in treatment, survival rates for high-risk and ...
Jan 23, 2025
0
13
In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine (T-DM1) reduced the long-term risk of death or invasive disease by 46% and improved survival compared ...
Jan 15, 2025
0
48
Cancer researchers at the University of Leicester have developed a technique that could predict how well some breast cancer patients will respond to chemotherapy and antibody-directed cancer treatments.
Jan 10, 2025
0
52
For dialysis-dependent patients treated for osteoporosis, denosumab is associated with a greater preventive effect on fractures but an increased risk for major adverse cardiovascular events (MACE) compared with oral bisphosphonates, ...
Jan 7, 2025
0
14
The U.S. Food and Drug Administration has approved Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) injection for subcutaneous use for most previously approved adult, solid tumor Opdivo (nivolumab) indications.
Jan 3, 2025
0
28
Since July 2024, faricimab has also been approved in Europe for the treatment of visual impairment due to macular edema secondary to retinal vein occlusion. The German Institute for Quality and Efficiency in Health Care (IQWiG) ...
Dec 30, 2024
0
20
